CND Life Sciences Highlights Neurodiagnostics Focus at Major Neurology Conference

According to a recent LinkedIn post from CND Life Sciences, the company participated in the American Academy of Neurology Annual Meeting in Chicago. The post indicates that its team engaged with the neurology community around the role of cutaneous alpha-synuclein in neurodiagnostics, including use of its Syn-One Test.

The LinkedIn post also notes interest in CND Life Sciences’ abstracts, posters, and presentations at the meeting. For investors, this presence at a major specialty conference may support clinician awareness, potential test adoption, and longer-term revenue growth, while reinforcing the firm’s positioning in neurology-focused diagnostic innovation.